A legacy of blood cancer innovation
A legacy of blood cancer innovation
angilma1
Fri, 05/31/2024 – 18:01
Read more about A legacy of blood cancer innovation
PrintPDF
Entries by angilma1
A legacy of blood cancer innovation
A legacy of blood cancer innovation
angilma1
Fri, 05/31/2024 – 18:01
Read more about A legacy of blood cancer innovation
PrintPDF
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
angilma1
Fri, 05/10/2024 – 10:14
Read more about Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
PrintPDF
Novartis Financial Results – Q1 2024
Novartis Financial Results – Q1 2024
angilma1
Thu, 04/18/2024 – 09:55
Read more about Novartis Financial Results – Q1 2024
PrintPDF
Novartis Appoints Sloan Simpson as Global Head of Investor Relations
Novartis Appoints Sloan Simpson as Global Head of Investor Relations
angilma1
Thu, 02/15/2024 – 09:51
Read more about Novartis Appoints Sloan Simpson as Global Head of Investor Relations
PrintPDF
Novartis at the J.P. Morgan Healthcare Conference 2024
Novartis at the J.P. Morgan Healthcare Conference 2024
angilma1
Thu, 01/04/2024 – 15:51
Read more about Novartis at the J.P. Morgan Healthcare Conference 2024
PrintPDF
Violence against innocent people runs counter to our work to improve human health
Violence against innocent people runs counter to our work to improve human health
angilma1
Wed, 10/18/2023 – 17:37
Read more about Violence against innocent people runs counter to our work to improve human health
PrintPDF
Violence against innocent people runs counter to our work to improve human health
Violence against innocent people runs counter to our work to improve human health
angilma1
Wed, 10/18/2023 – 17:31
Read more about Violence against innocent people runs counter to our work to improve human health
PrintPDF
